Breast cancer is the most frequently diagnosed female cancer in Poland (over 17,500 women). Anthracyclines have become one of the most important drugs in breast cancer systemic treatment. In the treatment of metastatic disease combination chemotherapy with doxorubicin provides the objective response rate of 60-85%, and the median time of progression-free survival is about 12 months.
IntroductIon
Malignant breast cancer is one of the most frequently diagnosed female tumours in Poland (over 17,500 female patients), and is the second cause of death for malignancies in women (ca. 5,000 deaths annually).
The 5-year survival rate in Poland is around 75% at present (while in Scandinavian countries, it amounts to ca. 85%).
Breast cancer incidence has also been on the rise, growing quicker than that of other cancers, though at the same time survival rates have gone up too (still lower in Poland than in most of the EU countries).
70% of Polish patients suffer from hormone-dependent HER2-negative breast cancer, in 30-40% of those treated at early stages of cancer development, there may be disease recurrence and distant metastases, and 5-6% of the breast cancer cases are diagnosed at an advanced stage already.
Anthracyclines are the main class of drugs administered in systemic breast cancer treatment. Discovered over 50 years ago, anthracycline antibiotics (isolated from Streptomyces bacteria) are amongst the most efficacious drugs used in anti-cancer therapy [1] .
In the treatment of metastatic disease, multi-drug regimens based on doxorubicin enable remission in 60-85% of the patients, with the mean duration of remission totalling ca. 12 months [2] .
The use of conventional anthracyclines is usually burdened with the risk of cardiovascular toxicity. Early and late symptoms of cardiotoxicity emerge in 5-23% of patients. They include reduced physical performance, and progressive signs of heart failure [3, 4] . Extreme cases of heart failure are diagnosed in 2-4% of patients [5] .
The risk of toxicity following the administration of doxorubicin is dose-dependent, and amounts to 5% at the cumulative dose of 400 mg/m 2 , increasing to as much as 25% at the dose of 700 mg/m 2 [6, 7] .
In patients with additional risk factors (age < 18 and > 65, concomitant cardiac diseases, e.g. hypertension, left ventricular hypertrophy, coronary heart disease, diabetes, prior radiotherapy), the total dose should not exceed 450 mg/m 2 [8] . Following anti-cancer treatment, the patient was under regular follow-up, and gave birth to 2 healthy daughters. Further diagnostic procedures were performed, focusing on the central nervous system, with brain MRI revealing 3 metastatic lesions. Following neurosurgical consultation, the patient was qualified for surgery. However, due to cardiac rhythm disturbances during anaesthesia, the surgery was aborted. Consequently, in
April 2016, the patient underwent palliative brain radiotherapy.
Chemotherapy was also continued, leading to partial metabolic response after 7 courses, as demonstrated in PET-CT, and a reduction in the Ca 15-3 concentration.
As the EMBRACA clinical study, dedicated to BRCA1 or BRCA2 mu- It is worth noting that NPLD therapy should be stopped in the case of symptomatic cardiotoxicity (LVEF drop of at least 10 points as compared with baseline, to a value below 53%, with symptoms of heart failure exacerbation). On the other hand, asymptomatic drop in LVEF by fewer than 10 points should not result in treatment cessation [12] .
The detected anthracycline-induced cardiomyopathy (LVEF < 45%) was subjected to standard treatment of systolic left ventricular dysfunction. Combination of an angiotensin-converting enzyme inhibitor and a β-adrenolytic is currently the best therapeutic option that improves the heart's systolic function and reduces mortality [13] .
When taking decisions on initiating NPLD treatment in patients with metastatic disease, one should take into account the time that has passed from the completion of adjuvant therapy with conventional doxorubicin to the spread of disease (at least 12 months). There should also be no advanced cardiovascular diseases involved (symptomatic NYHA III or IV heart failure, LVEF < 40%, sustained myocardial infarction < 6 weeks before, persistent ventricular tachycardia or ventricular fibrillation in the patient's history, uncontrolled arterial hypertension, unstable angina pectoris, grade III or IV) [14] .
In light of the potential cardiotoxicity related to the prior use of conventional doxorubicin, one should remember that the total lifetime dose should also be calculated as the sum of all doses of doxorubicin formulations (when using first-and second-generation anthracyclines, one has to count the doxorubicin equivalent doses) [15] .
The second case discussed involves a 51-year-old patient with advanced breast cancer (with liver, lung and bone metastases), who received 11 NPLD cycles as first-line treatment.
Due to the elevated liver enzymes, exceeding four times the upper limit of normal, the dose was reduced by 25%, starting from the fifth cycle, in accordance with the SmPC.
As NPLD is mainly metabolized in the liver, and excreted with bile, one should assess liver function before the initiation of treatment, and then follow-up on it throughout the therapy, adjusting the cytostatic dose to the liver enzymes and bilirubin levels, based on the recommendations included in the SmPC.
Treatment with NPLD may lead to myelosuppression. A meta-analysis, provided in the SmPC, demonstrated a significantEfficacy and safety of non-pegylated liposomal doxorubicin in metastatic breast cancer therapy E. Wójcik, J. Kufel-Grabowska, J. Gierba-Tomczyk ly lower incidence of grade 4 neutropenia, nausea and emesis, diarrhoea > grade 3, with no differences in terms of anaemia, thrombocytopenia and febrile neutropenia compared with conventional doxorubicin.
In the case of haematological toxicity, standard procedure involves extending the intervals between chemotherapy cycles or reducing the cytostatic dose.
The patient completed NPLD treatment following the eleventh cycle (total dose of 750 mg/m 2 ) due to persistent grade 2 fatigue, lasting for a week and a half, and in light of the continued partial remission of metastatic lesions.
Systemic treatment of stage IV breast cancer prolongs patient survival and improves the quality of life, but is not curative, which is why it is so important to limit treatment-induced toxicity, while at the same time accomplishing satisfactory therapeutic outcomes.
Non-pegylated liposomal doxorubicin has a role to play here due to its unique structure and pharmacokinetics.
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